MTOR and renal cell carcinoma: Novel data have shown that RCC exhibits constitutive activation of the phosphatidylinositol 3-kinase (PI3K) – Akt – mammalian target of rapamycin (mTOR) pathway, the downstream effector of VEGF and EGF receptor signaling [9,10].